Display options
Cite
Liedgens H, Obradovic M, De Courcy J, et al. A burden of illness study for neuropathic pain in Europe. Clinicoecon Outcomes Res. 2016;8:113-26doi: 10.2147/CEOR.S81396.
Liedgens, H., Obradovic, M., De Courcy, J., Holbrook, T., & Jakubanis, R. (2016). A burden of illness study for neuropathic pain in Europe. ClinicoEconomics and outcomes research : CEOR, 8113-26. https://doi.org/10.2147/CEOR.S81396
Liedgens, Hiltrud, et al. "A burden of illness study for neuropathic pain in Europe." ClinicoEconomics and outcomes research : CEOR vol. 8 (2016): 113-26. doi: https://doi.org/10.2147/CEOR.S81396
Liedgens H, Obradovic M, De Courcy J, Holbrook T, Jakubanis R. A burden of illness study for neuropathic pain in Europe. Clinicoecon Outcomes Res. 2016 Apr 27;8:113-26. doi: 10.2147/CEOR.S81396. eCollection 2016. PMID: 27217785; PMCID: PMC4853004.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2016 Apr 27;8:113-26. doi: 10.2147/CEOR.S81396. eCollection 2016.

A burden of illness study for neuropathic pain in Europe.

ClinicoEconomics and outcomes research : CEOR

Hiltrud Liedgens, Marko Obradovic, Jonathan De Courcy, Timothy Holbrook, Rafal Jakubanis

Affiliations

  1. Grunenthal, Aachen, Germany.
  2. Adelphi Real World, Bollington, Cheshire, UK.

PMID: 27217785 PMCID: PMC4853004 DOI: 10.2147/CEOR.S81396

Abstract

PURPOSE: Neuropathic pain (NP) is often severe and represents a major humanistic and economic burden. This study aimed at providing insight on this burden across France, Germany, Italy, Spain, and the UK, considering direct and indirect costs, productivity loss, and humanistic impact on patients and their families.

METHODS: Physician questionnaires provided data on patients presenting with NP covering demographics, sick leave and retirement, number of consultations, drug treatments, and surgical procedures. Patients provided further demographic and disease-related data and completed the Work Productivity and Activity Impairment (WPAI), the EuroQol 5-Dimension (EQ-5D), and the Brief Pain Inventory (BPI) questionnaires. All health-related direct unitary costs were collected from relevant country-specific sources and adjusted to 2012 prices (€) where necessary. A subgroup analysis of costs based on diabetic peripheral neuropathy (n=894), fibromyalgia (n=300), and low back pain (n=963) was performed.

FINDINGS: About 413 physicians completed a total of 3,956 patient records forms. Total annual direct health-care costs per patient ranged from €1,939 (Italy) to €3,131 (Spain). Annual professional caregiver costs ranged from €393 (France) to €1,242 (UK), but this only represented a small proportion of total care because much care is provided by family or friends. Sick leave costs ranged from €5,492 (UK) to €7,098 (France), with 10%-32% patients prevented from working at some point by NP. Total cost (including direct and indirect costs) of NP per patient was €10,313 in France (69% of the total cost), €14,446 in Germany (78%), €9,305 in Italy (69%), €10,597 in Spain (67%), and €9,685 in the UK (57%). Indirect costs (ie, sick leave) constituted the majority of costs in all five countries: €7,098 in France, €11,232 in Germany, €6,382 in Italy, €7,066 in Spain, and €5,492 in the UK. In the subgroup analysis, total annual direct costs per patient were highest for neuropathic back pain and radiculopathy, and lowest for fibromyalgia. Mean WPAI score range was 34.4-56.1; BPI interference was 4.1-4.8; and EQ-5D was 0.57-0.74. The results suggest that a significant proportion of the patient's work time in the previous week was affected by NP, and these are relatively high compared with other diseases such as diabetes, respiratory conditions, and arthritis.

IMPLICATIONS: Despite differences in practice between countries, these findings suggest a high opportunity cost for society in terms of lost work and productivity due to NP. The wider costs appear significantly higher to patients, carers/families, and society as a whole than to the health system alone.

Keywords: burden of illness; chronic lower back pain; neuropathic pain; productivity

References

  1. Clin J Pain. 2007 Feb;23(2):143-9 - PubMed
  2. Curr Med Res Opin. 2011 Feb;27(2):449-62 - PubMed
  3. Curr Med Res Opin. 2006 Oct;22(10):1911-20 - PubMed
  4. J Pain. 2004 Apr;5(3):143-9 - PubMed
  5. Pain. 2004 Dec;112(3):372-80 - PubMed
  6. J Med Econ. 2012;15(2):245-52 - PubMed
  7. Pharmacoeconomics. 2009;27(2):95-112 - PubMed
  8. Curr Pain Headache Rep. 2009 Jun;13(3):185-90 - PubMed
  9. Eur J Pain. 2009 Nov;13(10):1030-5 - PubMed
  10. Eur J Neurol. 2010 Sep;17(9):1113-e88 - PubMed
  11. Br J Rheumatol. 1997 May;36(5):551-9 - PubMed
  12. Eur J Pain. 2008 Aug;12(6):804-13 - PubMed
  13. Eur J Pain. 2006 Feb;10(2):127-35 - PubMed
  14. Qual Life Res. 1993 Jun;2(3):169-80 - PubMed
  15. J Pain. 2006 Apr;7(4):281-9 - PubMed
  16. J Pain Symptom Manage. 1996 Apr;11(4):203-17 - PubMed
  17. BMC Endocr Disord. 2013 Dec 19;13:59 - PubMed
  18. Curr Med Res Opin. 2008 Nov;24(11):3063-72 - PubMed
  19. Curr Med Res Opin. 2011 Jan;27(1):11-33 - PubMed
  20. Pain. 2008 Jun;136(3):380-7 - PubMed
  21. Eur J Pain. 2006 May;10(4):287-333 - PubMed
  22. Neurology. 2008 Apr 29;70(18):1630-5 - PubMed

Publication Types